Videos
Relapsed Multiple Myeloma What Every Patient Needs to Know Relapsed multiple myeloma can bring new challenges, but understanding your options can make a difference. In this video, Dr. Joseph Mikhael, Chief Medical Officer of the International Myeloma Foundation, answers the top Googled…
U.S. FDA Extends Review Period for Blenrep (belantamab mafodotin) for Relapsed or Refractory Myeloma
News Article
FDA Extends Review Period for Blenrep (belantamab mafodotin) for Relapsed or Refractory Myeloma
July 23, 2025—According to a press release from GSK, "the US Food and Drug Administration (FDA) has extended the review period for the Biologics License Application (BLA…
News Article
Health Canada Approves Blenrep (belantamab mafodotin) Combinations for Relapsed or Refractory Multiple Myeloma
July 23, 2025—According to a press release from GSK, "Health Canada has approved Blenrep (belantamab mafodotin for injection) in combination with bortezomib and…
Videos
PERSEUS (NCT03710603) compared DVRd vs VRd in transplant-eligible newly diagnosed multiple myeloma. DVRd significantly improved PFS, CR rates, and MRD negativity. Sustained MRD negativity (≥12 months) with DVRd correlated with superior 48-month PFS, supporting its NCCN recommendation.
…
News Article
European Commission Approves First Treatment for High-Risk Smoldering Multiple Myeloma
July 23, 2025—According to a press release from Johnson & Johnson, "the European Commission (EC) has approved a new indication for Darzalex® (daratumumab) subcutaneous (SC) formulation…
Videos
The IRAKLIA trial (NCT05405166) compared subcutaneous (SC) vs intravenous (IV) administration of Isatuximab (Isa) combined with Pomalidomide (Pd) in relapsed/refractory multiple myeloma (RRMM). Conducted with an investigational wearable injector, results demonstrated comparable efficacy (…
News Article
ODAC votes against belantamab mafodotin in combination with bortezomib and dexamethasone (3-5), and in combination with pomalidomide and dexamethasone (1-7); FDA extends review period for Blenrep, PDUFA action date moved to October 23, 2025
On Thursday,…
Videos
Anitocabtagene autoleucel (anito-cel), an anti-BCMA CAR T-cell therapy, is evaluated in the iMMagine-1 Phase 2 trial for relapsed/refractory multiple myeloma (RRMM). The study aims to assess safety and efficacy in heavily pretreated patients. Results show a high overall response rate (97%) with…
Videos
The phase III IsKia trial evaluated Isatuximab-carfilzomib-lenalidomide-dexamethasone (IsaKRd) vs KRd for transplant-eligible NDMM patients. IsaKRd significantly increased MRD negativity rates post-induction and consolidation. Light consolidation maintained 10-6 sustMRD negativity advantage,…
Videos
CARTITUDE-1 evaluated cilta-cel in heavily pretreated relapsed/refractory multiple myeloma (RRMM) patients with historically poor outcomes. At 60.3 months follow-up, 33% remained progression-free ≥5 years post-infusion, showing significant biomarker correlations and durable responses. Median…
Videos
Top 10 Myeloma Breakthroughs from ASCO & EHA: Frontline Therapy, Early & Late Relapse, and CAR T-cell Insights
Interested in the latest breakthroughs presented at ASCO and EHA this year? Dr. Joseph Mikhael, IMF Chief Medical Officer, condenses the top 10 multiple myeloma research…
News Article
At the end of every month, the International Myeloma Foundation Newsroom will feature a wrap-up of some of the most fascinating studies about multiple myeloma from medical journals. Here is the July 2025 edition.
The IMF team of medical editors has provided overviews of key studies. Yet, we…
Videos
Multiple Myeloma Q&A: Why Diagnosis Can Take 12+ Months, MGUS, Costs & FDA News
Answering your myeloma questions! Dr. Joseph Mikhael, Chief Medical Officer of the International Myeloma Foundation, tackles the most pressing concerns from patients and care partners—from why…
News Article
The International Myeloma Foundation’s Brian D. Novis Research Grants: Celebrating 30 Years of Paving the Way for Transformative Breakthroughs in Myeloma Research
STUDIO CITY, CA, July 10, 2025 — The International Myeloma Foundation (IMF) is proud to announce the 30th…
News Article
European Hematology Association (EHA) and the European Myeloma Network (EMN) Include Pepaxti in New Clinical Practice Guidelines for Relapsed/Refractory Multiple Myeloma (RRMM)
July 8, 2025—According to a press release from Oncopeptides, "its drug Pepaxti has been included…
Videos
Description:
Learn about bispecifics in multiple myeloma.
Module Objectives:
Review important concepts for bispecifics use in mutiple myeloma
Highlight important nursing considerations for patient education
Learn about the…
Page
What Is Lynozyfic (linvoseltamab-gcpt)?LYNOZYFIC™ (also known as linvoseltamab-gcpt , the generic drug name) is a B-cell maturation antigen (BCMA)-CD3-directed bispecific antibody immunotherapy. In July 2025, the U.S. FDA granted accelerated approval of Lynozyfic for the…
IMF Person
Kristina is a Certified Meeting Professional (CMP) with a decade of experience orchestrating diverse events, from large-scale corporate and medical conferences to intimate rare disease family gatherings and weddings. Her career began in-house with prominent associations like the New York State Bar…
Videos
Palliative Care in Multiple Myeloma: What It Really Means for Patients and Families
What is palliative care in multiple myeloma—and why is it so important? Dr. Joseph Mikhael, Chief Medical Officer of the International Myeloma Foundation, explains the role of palliative care in under a…
News Article
July 2, 2025—According to this press release from Regeneron Pharmaceuticals Inc., the "U.S. Food and Drug Administration (FDA) has granted accelerated approval for Lynozyfic™ (linvoseltamab-gcpt) to treat adult patients with relapsed or refractory (R/R) multiple myeloma (MM) who have…
News Article
The International Myeloma Foundation Proudly Announces we have completed and finalised the EMA-CHMP Qualification Advice to i2TEAMM Novel Biomarker Procedure Application on the Use of MRDnegCR as an Intermediate Early Endpoint for Conditional Market Approval in Myeloma Clinical Trials
Another…
Videos
DOWNLOAD SLIDES
News Article
FDA Eliminates Risk Evaluation and Mitigation Strategies (REMS) Program for Certain Autologous CAR T-cell Therapies
July 1, 2025—According to this press release from the U.S. Food and Drug Administration, "The U.S. Food and Drug Administration announced today that it has eliminated the…
News Article
U.S. FDA Removes Required REMS Program for Approval of Abecma (ide-cel) and for Breyanzi (liso-cel)
June 30, 2025—According to a June 26th press release from Bristol Myers Squibb (BMS), "the U.S. Food and Drug Administration (FDA) has approved label updates for both of its CAR T cell…
Videos
Elranatamab (ELRA), a BCMA-CD3 bispecific antibody, combined with lenalidomide ± daratumumab, showed promising efficacy and manageable safety in transplant-ineligible newly diagnosed multiple myeloma patients. MagnetisMM-6 Phase 3 trial (NCT05623020) evaluated ELRA in dose level G (DLG),…
News Article
June 27, 2025—In this article, Oncology Nursing News sat down with the International Myeloma Foundation's Interim CEO and Senior Vice President of Strategic Planning, Diane Moran, RN, MA, EdM, to discuss how healthcare providers, particularly nurses, contribute to transitioning myeloma care…
Videos
Talquetamab Side Effects: Managing Taste Loss, Hair & Nail Changes in Myeloma New bispecific antibodies like TALVEY® (talquetamab-tgvs) unlock a powerful way to attack multiple myeloma via the GPRC5D target—but they can cause unique side effects.In this Myeloma Made Simple episode, Dr.…
News Article
Led by IMF Director of Public Policy and Advocacy Danielle Doheny, the Coalition to Improve Access to Cancer Care (CIACC) applauds the reintroduction of the bipartisan bill.
WASHINGTON D.C. — On Tuesday, June 24, a group of bipartisan lawmakers —…
Videos
NEXICART-2 evaluates NXC-201 CAR-T in RR AL Amyloidosis, focusing on safety and efficacy outcomes. Results indicate rapid, deep hematologic responses with manageable toxicities, suggesting NXC-201 as a promising treatment.
Key Points:
Research Problem/Question:…
News Article
European CHMP Recommends Sarclisa (isatuximab-irfc) for Approval to Treat Transplant-Eligible Newly Diagnosed Multiple Myeloma
June 23, 2025—According to a press release from Sanofi, "The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a…
News Article
Darzalex (daratumumab) Receives Positive Opinion from European CHMP for High-Risk Smoldering Multiple Myeloma Patients
According to a press release from Johnson & Johnson, "the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the…
Videos
JNJ-5322, a next-generation bispecific antibody, targets BCMA and GPRC5D via T-cell redirection in patients with relapsed/refractory multiple myeloma. The phase 1 trial (NCT05652335) explored dose escalation up to 300 mg Q4W, identifying 100 mg Q4W as the recommended phase 2 dose. Results indicate…
Videos
Why 4 Drugs Work Better in Myeloma: Quadruplet Therapy Explained | Myeloma Made Simple
Should myeloma patients start with 2, 3, or 4 drugs? In this Myeloma Made Simple episode, Dr. Joseph Mikhael breaks down why quadruplet therapy (4 drug combination therapy) is now the new standard of…
News Article
At the end of every month, the International Myeloma Foundation Newsroom will feature a wrap-up of some of the most fascinating studies about multiple myeloma from medical journals. Here is the June 2025 edition.
The IMF team of medical editors has provided overviews of key studies. Yet, we…
News Article
Coinciding with the 16th Annual International Myeloma Working Group (IMWG) Summit in Milan, Italy, the Journal of Clinical Oncology recently published a peer-reviewed article on the “International Myeloma Society/International Myeloma…
Videos
Infection Management for Bispecific Antibodies: A Patient’s Guide
Bispecific antibodies are changing how we treat relapsed myeloma—but they can raise your risk of infection.
In this episode of Myeloma Made Simple, Dr. Joseph Mikhael breaks down how to reduce…
News Article
International Myeloma Foundation (IMF) Honors 2025 Kyle and Durie Achievement Awardees, Dr. Sagar Lonial and Dr. Sonja Zweegman
Awarding ceremonies held on June 10, 2025, at the 16th Annual IMWG Summit in Milano, Italy
MILANO, ITALY, June 10, 2025…
Videos
Top 10 Myeloma Questions Answered: CAR T, New Drugs & Exercise Tips
Dr. Joseph Mikhael, Chief Medical Officer of the International Myeloma Foundation, tackles the top 10 most searched multiple myeloma questions from our online community.
Learn if and…
News Article
Featured in Clinical Research News, International Myeloma Foundation Chief Medical Officer Dr. Joseph Mikhael talks about the IMF’s “overarching strategy as the convener of the broader myeloma community in ways that lead to improved outcomes for patients in terms of both their quality and quantity…
News Article
This week, important new data and results from several myeloma research trials were presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL. Johnson & Johnson released data from …
Videos
Coordinating Bispecific Antibodies for Multiple Myeloma: A Patient’s Guide
Bispecific antibodies have revolutionized treatment for relapsed/refractory multiple myeloma, but they require special coordination between your infusion center, community oncologist—and you, the patient…
Audio
Medspoke Interviews Myeloma Patient Phil Falkowitz and Care Partner Barbara Falkowitz About the IMF's Miracles for Myeloma 5K Walk/Run in Philadelphia
In this interview with Medspoke, recorded on April 30, 2025, Phil and Barbara Falkowitz, long-time pillars in the multiple myeloma community…
Audio
Medspoke Interviews Myeloma Patient Maryann Hauber About the IMF's Miracles for Myeloma 5K Walk/Run in Philadelphia
In this heartfelt interview recorded by Medspoke on April 30, 2025, myeloma patient and advocate Maryann Hauber shares her personal journey with multiple myeloma, from her…
Audio
Medspoke Interviews Myeloma Patient and Advocate Michael Riotto About the IMF's Miracles for Myeloma 5K Walk/Run in Philadelphia
For Michael Riatto, a myeloma survivor and event co-chair, this Miracles for Myeloma 5K Run/Walk is more than a race—it’s a symbol of hope, support, and…
News Article
CHMP of the European Medicines Agency Recommends Approval of Blenrep
May 23, 2025—According to a press release from GSK, "the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the approval of Blenrep for the…
IMF Person
Katie Atkins, LCSW, LCAS, CCS, OSW-C
Associate Director, Support Groups | Southeast
Katie has been working as a clinical social worker for the past 15 years, finding a niche in oncology social work 7 years ago. She most recently worked in an outpatient clinic, serving in the…